The United Kingdom has approved the use of a new drug, faricimab, which considerably reduces the frequency of treatments. From now on, patients will only require three injections per year, compared to one per month with current treatments. This medical progress could benefit more than 11,000 people in the United Kingdom, marking a major turning point in the treatment of this disease.
L’RVO, retinal vein occlusion, is a serious condition where a vein in the back of the eye becomes blocked due to a clot, causing fluid to leak into the retina. This causes bruising, swelling, and over time can lead to permanent vision loss. Each year, around 50,000 Britons are affected by this condition, mainly people aged over 60. Within two months of diagnosis, 80% of patients suffer from significant visual disturbances, including blurred vision.
Risk factors for RVO include hypertension blood pressure, high cholesterol, diabetes and smoking, although the exact cause of the disease is not always clearly identified. Until now, treatment required monthly injections directly into the eyea cumbersome and restrictive process for patients and the health system.
…
